In one of the studies, the authors analyzed the expression of YAP1 in 117 clinical samples of glioma, as indicated by the 2016 WHO classification, and demonstrated that YAP1 is strongly correlated with glioma molecular subtypes and patient prognosis. Here, YAP1 is linked to central nervous system cancer.